JUST IN: AstraZeneca’s Enhertu Gets EU’s Approval As Breast Cancer Treatment

JUST IN: AstraZeneca’s Enhertu Gets EU’s Approval As Breast Cancer Treatment—AstraZeneca and Daiichi Sankyo’s drug, Enhertu, has been approved by  the European Union for  treatment of  adult patients with an aggressive form of breast cancer.

AstraZeneca said on Tuesday that Enhertu coud be used as a monotherapy in cases with unresectable or metastatic HER2-positive breast cancer.

The treatment was jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.

The European Medicines Agency (EMA) gave its endorsement late in June.

The EMA said Enhertu was effective at shrinking the tumour in patients with metastatic breast cancer or breast cancer that could not be removed by surgery